类风湿关节炎患者常规诊疗中生物治疗减量与停用的2年结局及预测因素
143例持续缓解且影像学无进展的类风湿关节炎患者按治疗指南将生物改善病情抗风湿药减至标准剂量三分之二、16周减半、32周停用,141例完成2年随访;62%成功减量,16%成功停用,影像学进展9例(7%),≤1种既往生物制剂、男性、低基线MRI联合炎症/损伤评分为成功减量独立预测因素,IgM-RF阴性预测成功停用。
要点
- 持续缓解RA患者按指南减量bDMARD,2年时62%成功减量、16%成功停用、38%仍需全剂量。
- 2年影像学进展仅9例(7%),ΔDAS28-CRP中位数0.1,ΔTotal-Sharp-Score均值0.01。
- ≤1种既往bDMARD、男性、低基线MRI联合炎症/损伤评分独立预测成功减量;IgM-RF阴性预测成功停用。
核心结论
- 按临床指南实施减量后,常规诊疗中持续缓解的RA患者62%成功减量,其中16%在2年时成功停用,影像学进展少见。
- 最多1种既往bDMARD、男性、低基线MRI联合炎症评分及联合损伤评分为成功减量的独立预测因素,IgM-RF阴性预测成功停用。
研究设计与样本
- 常规诊疗队列研究,纳入143例持续缓解(DAS28-CRP≤2.6且前一年无影像学进展)的RA患者,91%使用TNF抑制剂、9%使用非TNF抑制剂。
- 基线将bDMARD减至标准剂量三分之二,16周减至半量,32周停用; flare(DAS28-CRP≥2.6且较基线ΔDAS28-CRP≥1.2,或X线/和MRI示侵蚀进展)者停止减量并恢复至前一剂量水平。
- 141例完成2年随访。
主要发现
- 2年时87例(62%)成功减量bDMARD:26例(18%)用标准剂量三分之二、39例(28%)用半量、22例(16%)已停用;54例(38%)仍用全剂量。
- ΔDAS28-CRP0-2年(中位数(四分位距))为0.1((-0.2)-0.4),ΔTotal-Sharp-Score0-2年(均值(标准差))为0.01(1.15)。
- 9例(7%)观察到影像学进展。
- 成功减量的独立预测因素:≤1种既往bDMARD、男性、低基线MRI联合炎症评分或联合损伤评分;IgM-RF阴性预测成功停用。
关键数值与推荐
- 持续缓解定义:DAS28-CRP≤2.6且前一年无影像学进展。
- flare定义:DAS28-CRP≥2.6且较基线ΔDAS28-CRP≥1.2,或X线/和MRI示侵蚀进展。
- 减量方案:基线减至标准剂量三分之二,16周减至半量,32周停用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A cohort of routine care RA patients in sustained remission had biological DMARD (bDMARDs) tapered according to a treatment guideline. We studied: the proportion of patients whose bDMARD could be successfully tapered or discontinued; unwanted consequences of tapering/discontinuation; and potential baseline predictors of successful tapering and discontinuation. METHODS: One-hundred-and-forty-three patients (91% receiving TNF inhibitor and 9% a non-TNF inhibitor) with sustained disease activity score (DAS28-CRP)⩽2.6 and no radiographic progression the previous year were included. bDMARD was reduced to two-thirds of standard dose at baseline, half after 16 weeks, and discontinued after 32 weeks. Patients who flared (defined as either DAS28-CRP ⩾ 2.6 and ΔDAS28-CRP ⩾ 1.2 from baseline, or erosive progression on X-ray and/or MRI) stopped tapering and were escalated to the previous dose level. RESULTS: One-hundred-and-forty-one patients completed 2-year follow-up. At 2 years, 87 patients (62%) had successfully tapered bDMARDs, with 26 (18%) receiving two-thirds of standard dose, 39 (28%) half dose and 22 (16%) having discontinued; and 54 patients (38%) were receiving full dose. ΔDAS28-CRP0-2yrs was 0.1((-0.2)-0.4) (median (interquartile range)) and mean ΔTotal-Sharp-Score0-2yrs was 0.01(1.15)(mean(s.d.)). Radiographic progression was observed in nine patients (7%). Successful tapering was independently predicted by: ⩽1 previous bDMARD, male gender, low baseline MRI combined inflammation score or combined damage score. Negative IgM-RF predicted successful discontinuation. CONCLUSION: By implementing a clinical guideline, 62% of RA patients in sustained remission in routine care were successfully tapered, including 16% successfully discontinued at 2 years. Radiographic progression was rare. Maximum one bDMARDs, male gender, and low baseline MRI combined inflammation and combined damage scores were independent predictors for successful tapering.
引用
- Brahe CH, Krabbe S, Østergaard M, et al. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors. Rheumatology (Oxford). 2019. PMID: 30169706. doi:10.1093/rheumatology/key244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。